Experimental Drug Shows Promise in Reducing Visceral Fat
A mid-stage study finds an injectable drug may help adults reduce abdominal fat and related metabolic risks.
Updated on Oct. 21, 2026 in Weight Loss
Live Poll
Would you prefer a weight loss treatment that targets fat directly rather than suppressing your appetite?
Researchers have reported that an experimental injectable drug, CBL-514, successfully reduced abdominal visceral fat in a mid-stage clinical trial. The findings, presented in Milan, highlight a potential new approach to addressing fat tissue linked to chronic health conditions.
Why it matters
Visceral fat is closely linked to significant health risks, including insulin resistance, type 2 diabetes, and cardiovascular disease. New treatment options that target fat reduction could provide important tools for managing these metabolic risks.
This Phase 2 randomized clinical trial analyzed MRI data from 40 participants who received abdominal injections for up to 12 weeks. Results show a 12.01% average reduction in visceral fat volume four weeks post-treatment, compared to a 5.68% increase in the placebo group.
The details
The experimental drug CBL-514 is injected directly into the lower abdomen to target fat cells. It functions by inducing adipocyte apoptosis, or programmed cell death, in the targeted tissue. Previous research has noted that participants may experience injection-site reactions such as pain, swelling, or redness.
Timeline
Four weeks after the final injection, the treatment group showed a 12.01% visceral fat reduction.
Eight to 12 weeks after treatment, the treatment group maintained a 10.45% visceral fat reduction.
Health Landscape
This study explores a localized alternative to the systemic weight-loss strategies currently defined by the development of GLP-1 receptor agonist medications. Researchers are now investigating whether this approach can help patients maintain weight loss after stopping systemic therapies.
While these findings offer a new potential treatment route, it is important to note that the drug is still in early-stage testing and is not currently available for public use. Any questions about managing visceral fat or weight-related health risks are best discussed with a physician.
The takeaway
Targeting visceral fat may offer a specific pathway to reducing the risk of conditions like diabetes and heart disease. If you are concerned about your body composition, discuss your health history and safe management options with your primary care physician.
Further reading
Learn more about current approaches to metabolic health in our Weight Loss section.
Source note: This article includes information reported by Labroots.
Live Poll
Would you prefer a weight loss treatment that targets fat directly rather than suppressing your appetite?
